SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...
Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone ...
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...
Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added toxicity MOUNTAIN VIEW, Calif., January 08, 2026--(BUSINESS WIRE)--Osel Inc., a ...
Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...
Gender disparity in authorship of clinical trials leading to cancer drug approvals between 2008 and 2018: The glass ceiling of academic oncology. This is an ASCO Meeting Abstract from the 2022 ASCO ...
Researchers from SWOG Cancer Research Network have significantly extended median survival for patients with hormone-sensitive metastatic prostate cancer. This result comes from a large randomized ...
Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results